International germ cell consensus classification: A prognostic factor- based staging system for metastatic germ cell cancers

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 594-603

  Mead, G M ^a  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER STAGING; DIGESTIVE SYSTEM CANCER; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA;

EID: 0031037241     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.594     Document Type: Article

References (32)

1. Moller H: Clues to the aetiology of testicular germ cell tumours from descriptive epidemiology. Eur Urol 23:8-15, 1993
2. Samuels ML, Holoye TY, Johnson DE: Bleomycin combination chemotherapy in the management of testicular neoplasms. Cancer 36:318-326, 1975
3. Peckham MJ, McElwain TJ, Barrett A, et al.: Combined management of malignant teratoma of the testis. Lancet 2:267-270, 1979
4. Bosl GJ, Geller NL, Cirrincione C, et al.: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407, 1983
5. Medical Research Council: Prognostic factors in advanced nonseminomatous germ-cell testicular tumours: Results of a multicentre study. Lancet 1:8-12, 1985
6. Birch R, Williams S, Cone A, et al.: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
7. Newlands ES, Bagshawe KD, Begent RHJ, et al.: Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol 58:307-314, 1986
8. Stoter G, Sylvester R, Sleijfer DT, et al.: Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from an EORTC multiinstitutional phase III study. Cancer Res 47:2414-2718, 1987
9. Droz JP, Kramar A, Ghosn M, et al.: Prognostic factors in advanced nonseminomatous testicular cancer. Cancer 62:564-568, 1988
10. Aass N, Klepp O, Stahl-Cavallin E, et al.: Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicentre experience. J Clin Oncol 9:818-826, 1991
11. Mead GM, Stenning SP, Parkinson MC, et al.: The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumours. J Clin Oncol 10:85-94, 1992
12. Bajorin D, Katz A, Chan E, et al.: Comparison of criteria for assigning germ cell tumour patients to "good risk" and "poor risk" studies. J Clin Oncol 6:786-792, 1988
13. Hitchins RN, Newlands ES, Smith DB, et al.: Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: Comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 59:236-242, 1989
14. Chilvers CED, Fayers PM, Freedman LS, et al.: Improving the quality of data in randomised clinical trials - The COMPACT computer package. Stat Med 7:1165-1170, 1988
15. Horwich A, Sleijfer D, Fossa S, et al.: A trial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular non seminoma. Proc Am Soc Clin Oncol 13:231, 1994(abstr)
16. Kaye SB, Mead GM, Fossa S, et al.: An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP. Proc Am Soc Clin Oncol 14:246, 1995 (abstr)
17. 16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumours: An intergroup trial. Proc Am Soc Clin Oncol 14:239, 1995 (abstr)
18. Atkin NB, Baker MC: Specific chromosome change i(12p) in testicular tumour? Lancet 2:1249, 1992
19. Toner GC, Geller NL, Shiow-Yin Lin NS, et al.: Extragonadal and poor risk non-seminomatous germ cell tumors. Cancer 67:2049-2057, 1991
20. Broun ER, Nichols CR, Einhorn LH, et al.: Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumours. Cancer 68:1513-1515, 1991
21. Daugaard G, Rorth M, von der Maase H, et al.: Management of extragonadal germ-cell tumours and the significance of bilateral testicular biopsies. Ann Oncol 3:283-289, 1992
22. Marcillac I, Troalen F, Bidart JM, et al.: Free human chorionic gonadotropin B submit in gonadal and nongonadal neoplasms. Cancer Res 52:3901-3907, 1992
23. Loehrer PJ, Johnson D, Elson P, et al.: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
24. Levi JA, Raghavan D, Harvey V, et al.: The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 11:1300-1305, 1993
25. Einhorn LH, Williams SD, Loehrer PJ, et al.: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
26. Nichols CR, Williams SD, Loehrer PJ, et al.: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
27. Horwich A, Dearnaley DP, Norman A, et al.: Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer 30A:1607-1611, 1994
28. Siegert W, Beyer J, Stohscheer I, et al.: High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 12:1223-1231, 1994
29. Broun RE, Nichols CR, Kneebone P, et al.: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
30. Motzer RJ, Mazumdar M, Gulati SC, et al.: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
31. Bokemeyer C, Schmoll HJ, Harstrick A, et al.: A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer 29A:2225-2231, 1993
32. Chevreau C, Pico JL, Kervrat P, et al.: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Eur Urol 23:213-218, 1993